Unity Biotechnology (Unity Biotechnology) Debt-to-Equity : 0.95 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Debt-to-Equity?

Unity Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.45 Mil. Unity Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $23.54 Mil. Unity Biotechnology's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $28.40 Mil. Unity Biotechnology's debt to equity for the quarter that ended in Dec. 2023 was 0.95.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Unity Biotechnology's Debt-to-Equity or its related term are showing as below:

UBX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.77 Med: 0.92 Max: 0.95
Current: 0.95

During the past 8 years, the highest Debt-to-Equity Ratio of Unity Biotechnology was 0.95. The lowest was 0.77. And the median was 0.92.

UBX's Debt-to-Equity is ranked worse than
86.66% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs UBX: 0.95

Unity Biotechnology Debt-to-Equity Historical Data

The historical data trend for Unity Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Debt-to-Equity Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.77

0.94

0.90

0.95

Unity Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.90	0.80	0.87	0.68	0.95

Competitive Comparison of Unity Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, Unity Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unity Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Debt-to-Equity falls into.

Unity Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Unity Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.451	+	23.539)	/	28.398
	=	0.95

Unity Biotechnology's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.451	+	23.539)	/	28.398
	=	0.95

Unity Biotechnology (NAS:UBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Unity Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology (Unity Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

9U90:Germany 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Executives

Anirvan Ghosh	director, officer: Chief Executive Officer	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar	director	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen	officer: See Remarks	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David	director, officer: President	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill	director	215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy	officer: See Remarks	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan	officer: See Remarks	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns	director	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels	director	2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess	officer: Chief Scientific Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005